← Back to all trials
Completed
NCT05500586
The Effects of Glucagon on Hepatic Metabolism
Conditions: Obesity, Type2diabetes, NAFLD
Sex: All
Ages: 25 Years – 65 Years
Healthy volunteers: Yes
Phase: PHASE1, PHASE2
Enrollment: 21
Sponsor: Adrian Vella
Location: Mayo Clinic in Rochester Rochester Minnesota
Summary
Whether impaired postprandial glucagon suppression in prediabetes and T2DM is an attempt to overcome resistance to glucagon's actions on hepatic AA catabolism, a defect in α-cell function, or a combination of both are important, unanswered questions. NAFLD is associated with T2DM risk and impaired insulin action. Unfortunately, it is unclear if glucagon resistance is caused by obesity, hepatic steatosis or both. The experiments outlined will determine if glucagon's actions on hepatic amino acid catabolism and EGP interact with hepatic lipid metabolism in lean and obese subjects with and without T2DM (and with varying degrees of hepatic steatosis).
Eligibility Criteria
Inclusion Criteria - Obese Subjects with Type 2 Diabetes:
* Type 2 diabetes
* BMI ≥ 28 Kg/M2
* Managed by diet alone or a combination of metformin and/or sulfonylurea
* Willing to stop glucose-lowering medication for 3 weeks prior to participation and willing to self-monitor their fasting glucose during this time
* No history of micro- or macrovascular complications of T2DM
Exclusion Criteria - Obese Subjects with Type 2 Diabetes:
* Age \< 25 or \> 65 years
* HbA1c ≥ 8.5%
* BMI ≤ 28 Kg/M2
* For female subjects: positive pregnancy test at the time of enrollment or study
* History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
* Active systemic illness or malignancy.
* Symptomatic macrovascular or microvascular disease.
* Known contraindications to MRI
* Hematocrit \< 35%
* History of uncontrolled thyroid disease
* Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire.
* Allergy to iodine
* Thrombocytopenia, history of bleeding disorder or use of anticoagulation
* Subjects with treatment change or significant weight change (≥ 10%) in the prior 3 months.
Inclusion Criteria - Obese subjects without Type 2 Diabetes:
-Obese subjects without type 2 diabetes but are age, sex and weight-matched (BMI ≥ 28 Kg/M2) with subjects who have T2DM
Exclusion Criteria - Obese Subjects without Type 2 Diabetes:
* Age \< 25 or \> 65 years (match subjects with T2DM)
* HbA1c ≥ 6.5%
* BMI ≤ 28 Kg/M2
* Use of any glucose-lowering agents
* For female subjects: positive pregnancy test at the time of enrollment or study
* History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
* Active systemic illness or malignancy.
* Symptomatic macrovascular or microvascular disease.
* Known contraindications to MRI
* Hematocrit \< 35%
* History of uncontrolled thyroid disease.
* Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire.
* Allergy to iodine
* Thrombocytopenia, history of bleeding disorder or use of anticoagulation
Inclusion Criteria - Lean subjects without Diabetes:
-Subjects who do not have type 2 diabetes but are age and sex but are not weight-matched (BMI ≤ 25 Kg/M2) with subjects who have T2DM
Exclusion Criteria - Lean subjects without Diabetes:
* Age \< 25 or \> 65 years (match subjects with T2DM)
* HbA1c ≥ 6.5%
* BMI ≥ 25 Kg/M2 unless % body fat is \< 20% in males and \< 30% in females.
* Use of any glucose-lowering agents
* For female subjects: positive pregnancy test at the time of enrollment or study
* History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
* Active systemic illness or malignancy.
* Symptomatic macrovascular or microvascular disease.
* Known contraindications to MRI
* Hematocrit \< 35%
* History of uncontrolled thyroid disease.
* Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire.
* Liver fat content ≥ 5% as determined by MRI using the proton density fat fraction (PDFF) technique.
* Allergy to iodine
* Thrombocytopenia, history of bleeding disorder or use of anticoagulation
Source: ClinicalTrials.gov (NCT05500586). StuddyBuddy aggregates publicly available trial information.